Avis Budget Group Inc. (CAR)

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed...

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .

Shares of Avis Budget Group (CAR -5.54%) coughed and sputtered like a stalling car on Hump Day, shedding almost 6% of their price across the trading session. That was almost entirely due to the news t...

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of ...

Avis Budget Group CAR shares are trading lower after BofA Securities analyst Federico Merendi downgraded the stock from Buy to Underperform and cut its price target from $120 to $113.

CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.

Shares of Avis Budget Group (CAR -14.80%) were moving in the wrong direction today after the rental car leader came up short in its second-quarter earnings report.

Avis Budget Group, Inc. (NASDAQ:CAR ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Brian J. Choi - Chief Executive Officer David T.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.